And he says imaging studies like ENHANCE have not been proven to be any more meaningful that reductions in LDL or C-reactive protein(CRP), a marker of inflammation.
If the FDA adopts the panel's recommendation -- the agency isn't required to do so, but typically does in such cases -- it would mark the first time that a statin was approved for heart-disease-free people with healthy cholesterol levels but other risk factors, including high levels of C-reactive protein(CRP), a marker of inflammation.